Skip to content
2000
  1. Home
  2. Volume 20, Issue 1
  3. Article
  • E-ISSN:
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background:

The liver plays a significant role in the digestive system, and disease in the liver initiates various other problems. The liver is severely affected due to alcohol use, and it initiates various chronic diseases, including Alcohol-Related Liver Disease (ARLD). Alcoholic/Nonalcoholic Fatty Liver Disease (AFLD/NFLD) is a severe medical emergency, and early screening and treatment are necessary to cure the patient. The untreated AFLD/NFLD will cause various problems, including fatigue, weight loss, and discomfort in the abdomen.

Objective:

This study aims to present a detailed review and investigation of schemes considered in medical clinics to identify the AFLD/NFLD coupled problems and present the merit of the Transient Elastography (TE) combined with Fibroscan® practice to identify liver abnormality.

Methods:

This research aims to study the clinical significance and the accuracy of TE-supported liver illness screening.

Results:

This work aims to collect the recent research works and clinical reports published from 2011 to 2021 from the chosen databases and provide a detailed review using the clinical information discussed in the selected articles.

Conclusion:

The essential statistical investigation of the collected data is executed with Review Manager (RevMan®) software, and the significance of the TE is confirmed using the articles supporting a 2x2 contingency table, and each case is evaluated using a p-score and the Region of Convergence (RoC) curve for 95% confidence intervals.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmim/10.2174/1573405619666230223092125
2023-05-08
2025-01-25

  • From This Site

    /content/journals/cmim/10.2174/1573405619666230223092125
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmim/20/1/e230223213941.html?itemId=/content/journals/cmim/10.2174/1573405619666230223092125&mimeType=html&fmt=ahah

References

  1. EslamM. GeorgeJ. MAFLD: A holistic view to redefining fatty liver disease.J. Hepatol.202174498398510.1016/j.jhep.2020.12.02733453330
     [Google Scholar]
  2. FouadY. GomaaA. SemidaN. GhanyW.A. AttiaD. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.J. Hepatol.20217451254125610.1016/j.jhep.2020.12.03533582129
     [Google Scholar]
  3. ByrneC.D. TargherG. Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications.Diabetes Obes. Metab.202110.1111/dom.1448434324263
     [Google Scholar]
  4. BalakrishnanM. PatelP. Dunn-ValadezS. DaoC. KhanV. AliH. El-SeragL. HernaezR. SissonA. ThriftA.P. LiuY. El-SeragH.B. KanwalF. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: A systematic review and meta-analysis.Clin. Gastroenterol. Hepatol.20211916171.e1510.1016/j.cgh.2020.04.06732360810
     [Google Scholar]
  5. ErdenA. Kuru ÖzD. PekerE. KulM. Özalp AteşF.S. ErdenI. İdilmanR. MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction.Diagn. Interv. Radiol.202127171410.5152/dir.2020.1965433290237
     [Google Scholar]
  6. SharptonS.R. TamakiN. BettencourtR. MadambaE. JungJ. LiuA. BehlingC. ValasekM.A. LoombaR. Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease.Therap. Adv. Gastroenterol.20211410.1177/1756284821105043634646360
     [Google Scholar]
  7. TaibbiA. PettaS. MatrangaD. CaruanaG. CannellaR. BusèG. MarcoV.D. MidiriM. BartolottaT.V. Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography.Ultrasonography202140340741610.14366/usg.2014733561928
     [Google Scholar]
  8. JungC.Y. RyuG.W. KimH.W. AhnS.H. KimS.U. KimB.S. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.Diabetologia202165351852710.1007/s00125‑021‑05627‑934932136
     [Google Scholar]
  9. Case courtesy of Dr Ayush Goel. Available from:https://radiopaedia.org/?lang=us Available from:https://radiopaedia.org/cases/33281?lang=us
  10. Case courtesy of Dr Bruno Di Muzio Available from:https://radiopaedia.org/?lang=us Available from:https://radiopaedia.org/cases/80805?lang=us
  11. ToshikuniN. TsutsumiM. ArisawaT. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.World J. Gastroenterol.201420268393840610.3748/wjg.v20.i26.839325024597
     [Google Scholar]
  12. CaiC. SongX. ChenX. ZhouW. JinQ. ChenS. JiF. Transient elastography in alcoholic liver disease and nonalcoholic fatty liver disease: A systemic review and meta-analysis.Can. J. Gastroenterol. Hepatol.2021202111010.1155/2021/885933833542909
     [Google Scholar]
  13. KarlasT. DietrichA. PeterV. WittekindC. LichtinghagenR. GarnovN. LinderN. SchaudinnA. BusseH. PrettinC. KeimV. TröltzschM. SchützT. WiegandJ. Evaluation of transient elastography, acoustic radiation force impulse imaging (ARFI), and enhanced liver function (ELF) score for detection of fibrosis in morbidly obese patients.PLoS One20151011e014164910.1371/journal.pone.014164926528818
     [Google Scholar]
  14. QiX. AnM. WuT. JiangD. PengM. WangW. WangJ. ZhangC. CHESS Study Group O. B. O. T. (2018). Transient elastography for significant liver fibrosis and cirrhosis in chronic hepatitis B: A meta-analysis.Can. J. Gastroenterol. Hepatol.2018201811310.1155/2018/340678929977884
     [Google Scholar]
  15. ChengJ. HouJ. DingH. ChenG. XieQ. WangY. ZengM. OuX. MaH. JiaJ. Validation of ten noninvasive diagnostic models for prediction of liver fbrosis in patients with chronic hepatitis B.PLoS One20151012e014442510.1371/journal.pone.014442526709706
     [Google Scholar]
  16. ViganòM. PaggiS. LamperticoP. FraquelliM. MassironiS. RonchiG. RigamontiC. ConteD. ColomboM. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: A cohort study with internal validation.Aliment. Pharmacol. Ther.201134335336210.1111/j.1365‑2036.2011.04722.x21631559
     [Google Scholar]
  17. KimS.U. KimJ.K. ParkJ.Y. AhnS.H. LeeJ.M. BaatarkhuuO. ChoiE.H. HanK.H. ChonC.Y. KimD.Y. Variability in liver stiffness values from different intercostal spaces.Liver Int.200929576076610.1111/j.1478‑3231.2009.02035.x19413672
     [Google Scholar]
  18. LiY. HuangY.S. WangZ.Z. YangZ.R. SunF. ZhanS.Y. LiuX.E. ZhuangH. Systematic review with meta-analysis: The diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B.Aliment. Pharmacol. Ther.201643445846910.1111/apt.1348826669632
     [Google Scholar]
  19. Available from:https://www.racgp.org.au/afp/2013/july/fibroscan
  20. ChoE.J. JungG.C. KwakM.S. YangJ.I. YimJ.Y. YuS.J. ChungG.E. Fatty liver index for predicting nonalcoholic fatty liver disease in an asymptomatic Korean population.Diagnostics20211112223310.3390/diagnostics1112223334943469
     [Google Scholar]
  21. CastellanaM. DonghiaR. GuerraV. ProcinoF. LampignanoL. CastellanaF. ZupoR. SardoneR. De PergolaG. RomanelliF. TrimboliP. GiannelliG. Performance of fatty liver index in identifying non-alcoholic fatty liver disease in population studies. A meta-analysis.J. Clin. Med.2021109187710.3390/jcm1009187733925992
     [Google Scholar]
  22. PopaS.L. IsmaielA. CristinaP. CristinaM. ChiarioniG. DavidL. DumitrascuD.L. Non-alcoholic fatty liver disease: implementing complete automated diagnosis and staging. A systematic review.Diagnostics2021116107810.3390/diagnostics1106107834204822
     [Google Scholar]
  23. Méndez-SánchezN. Díaz-OrozcoL. Córdova-GallardoJ. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.J. Hepatol.202175122122210.1016/j.jhep.2021.04.02133892008
     [Google Scholar]
  24. AlqahtaniS.A. SchattenbergJ.M. Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice.Expert Rev. Mol. Diagn.202121101065107810.1080/14737159.2021.196495834346799
     [Google Scholar]
  25. TanS.S. LeeY.Y. AliR.A.R. MustaphaF. ChanW.K. Endorsing the redefinition of fatty liver disease.Lancet Gastroenterol. Hepatol.20216316310.1016/S2468‑1253(21)00002‑933581757
     [Google Scholar]
  26. MakriE. GoulasA. PolyzosS.A. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease.Arch. Med. Res.2021521253710.1016/j.arcmed.2020.11.01033334622
     [Google Scholar]
  27. SfikasG. PsallasM. KoumarasC. ImprialosK. PerdikakisE. DoumasM. GioulemeO. KaragiannisA. AthyrosV.G. Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. do genetics play a role?Curr. Vasc. Pharmacol.202119557258110.2174/18756212MTEweNjkfy33059580
     [Google Scholar]
  28. ForlanoR. MullishB.H. NathwaniR. DharA. ThurszM.R. ManousouP. Non-alcoholic fatty liver disease and vascular disease.Curr. Vasc. Pharmacol.202119326927910.2174/18756212MTA1eMzMr332188385
     [Google Scholar]
  29. JorgačevićB. VučevićD. SamardžićJ. MladenovićD. VeskovićM. VukićevićD. JešićR. RadosavljevićT. The effect of CB1 antagonism on hepatic oxidative/nitrosative stress and inflammation in nonalcoholic fatty liver disease.Curr. Med. Chem.202028116918010.2174/092986732766620030312273432124686
     [Google Scholar]
  30. Godinez-LeivaE. BrilF. Nonalcoholic fatty liver disease (NAFLD) for primary care providers: Beyond the liver.Curr. Hypertens. Rev.20211729411110.2174/157340211699920120920353433302841
     [Google Scholar]
  31. MuzurovićE. SmolovićB. VujoševićS. PetakovM. Editorial on prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?Curr. Vasc. Pharmacol.202119558258410.2174/157016111866620100816253733032512
     [Google Scholar]
  32. XuL. PengA.K. CaoY. QiaoX. YueS.S. YeM. QiR. Protective effects of antrodia cinnamomea and its constituent compound dehydroeburicoic acid 32 against alcoholic fatty liver disease.Curr. Mol. Pharmacol.202114587188210.2174/187446721466621012015214033494689
     [Google Scholar]
  33. PalliniG. TsochatzisE.A. NAFLD: Diagnostic algorithms for regulating patient fluxes.Curr. Pharm. Des.202127273036304610.2174/138161282766621012712074833504297
     [Google Scholar]
  34. WangA. YueS. PengA. QiR. A review of research progress on agathis dammara and its application prospects for cardiovascular diseases and fatty liver disease.Mini Rev. Med. Chem.202121667067610.2174/138955752066620111711083433208073
     [Google Scholar]
  35. ThapaK. GrewalA.S. KanojiaN. RaniL. SharmaN. SinghS. Alcoholic and non-alcoholic liver diseases: Promising molecular drug targets and their clinical development.Curr. Drug Discov. Technol.202118333335310.2174/157016381766620012114395931965945
     [Google Scholar]
  36. FernandesG.W. BoccoB.M.L.C. Hepatic mediators of lipid metabolism and ketogenesis: Focus on fatty liver and diabetes.Curr. Diabetes Rev.2021177e11032018753910.2174/157339981699920110314121633143628
     [Google Scholar]
  37. JonesG.S. AlvarezC.S. GraubardB.I. McGlynnK.A. Agreement between the prevalence of nonalcoholic fatty liver disease determined by transient Elastography and fatty liver indices.Clin. Gastroenterol. Hepatol.2022201227229.e210.1016/j.cgh.2020.11.02833227430
     [Google Scholar]
  38. Unalp-AridaA. RuhlC.E. Transient elastography–assessed hepatic steatosis and fibrosis are associated with body composition in the United States.Clin. Gastroenterol. Hepatol.2022204e808e83010.1016/j.cgh.2021.02.00933549867
     [Google Scholar]
  39. HerediaN.I. ZhangX. BalakrishnanM. HwangJ.P. ThriftA.P. Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among hispanic/latinos adults in the U.S.Ethn. Health202211410.1080/13557858.2022.202788335067116
     [Google Scholar]
  40. KreimeyerH. BuechterM. BestJ. GieselerR.K. KatsounasA. SowaJ.P. GerkenG. CanbayA. MankaP. BechmannL.P. Performance of the liver maximum function capacity test, fibrinogen, and transient elastography in patients with acute liver injury.Dig. Dis.20221910.1159/000523696
     [Google Scholar]
  41. SiddiquiM.S. BuiA.T. SyedT. TsengM. HassounehR. BhatiC.S. Performance of vibration-controlled transient elastography and clinical prediction models in liver transplant recipients.Clin. Gastroenterol. Hepatol.2022S1542-3565(22)00149-510.1016/j.cgh.2022.02.02335181567
     [Google Scholar]
  42. YeungF. FungA.C.H. ChungP.H.Y. ChuY.Y. SetoW.K. WongK.K.Y. Long-term follow-up of biliary atresia using liver transient elastography.Pediatr. Surg. Int.20223871013101810.1007/s00383‑022‑05137‑835523886
     [Google Scholar]
  43. BraalC.L. de KnegtR.J. JagerA. KoolenS.L.W. MathijssenR.H.J. EechouteK. Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation.Hepatol. Commun.2022692565256810.1002/hep4.200835689385
     [Google Scholar]
  44. SubhaniM. HarmanD.J. ScottR.A. BennettL. WilkesE.A. JamesM.W. AithalG.P. RyderS.D. GuhaI.N. Transient elastography in community alcohol services: Can it detect significant liver disease and impact drinking behaviour?Biomedicines202210247710.3390/biomedicines1002047735203686
     [Google Scholar]
  45. DanaJ. GirardM. Franchi-AbellaS. BertelootL. Benoit-CherifiM. Imbert-BismutF. Sermet-GaudelusI. DebrayD. Comparison of transient elastography, shearwave elastography, magnetic resonance elastography and fibrotest as routine diagnostic markers for assessing liver fibrosis in children with cystic fibrosis.Clin. Res. Hepatol. Gastroenterol.202246310185510.1016/j.clinre.2021.10185534933150
     [Google Scholar]
  46. AliA.H. Al JubooriA. PetroskiG.F. Diaz-AriasA.A. Syed-AbdulM.M. WheelerA.A. GangaR.R. PittJ.B. SpencerN.M. HammoudG.M. RectorR.S. ParksE.J. IbdahJ.A. The utility and diagnostic accuracy of transient elastography in adults with morbid obesity: A prospective study.J. Clin. Med.2022115120110.3390/jcm1105120135268293
     [Google Scholar]
  47. ShenM. LeeA. LefkowitchJ.H. WormanH.J. Vibration-controlled transient elastography for assessment of liver fibrosis at a usa academic medical center.J. Clin. Transl. Hepatol.202210219720610.14218/JCTH.2021.0018835528980
     [Google Scholar]
  48. ArgaliaG. VenturaC. TosiN. CampioniD. TagliatiC. TufillaroM. CuccoM. SvegliatiB.G. GiovagnoniA. Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD.Radiol. Med.2022127557157610.1007/s11547‑022‑01475‑835290569
     [Google Scholar]
  49. ChanY.J. ChangS.S. WuJ.L. WangS.T. YuC.S. Association between liver stiffness measurement by transient elastography and chronic kidney disease.Medicine (Baltimore)20221014e2865810.1097/MD.000000000002865835089208
     [Google Scholar]
  50. ShearerJ.E. JonesR. ParkerR. FergusonJ. RoweI.A. The natural history of advanced chronic liver disease defined by transient elastography.Clin. Gastroenterol. Hepatol.2022S1542-3565(22)00290-710.1016/j.cgh.2022.03.01535337981
     [Google Scholar]
  51. DingY. JiangL. WangQ. ZhaoW. ZhouX. LuJ. TianT. YuC. XuX. GuoW. ZhangQ. SongC. The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.Clin. Res. Hepatol. Gastroenterol.202246810195110.1016/j.clinre.2022.10195135605893
     [Google Scholar]
  52. Al-MaweriS.A. AlhajjM.N. DeshishaE.A. AlshafeiA.K. AhmedA.I. AlmudayfiN.O. AlshammariS.A. AlsharifA. KassimS. Curcumin mouthwashes versus chlorhexidine in controlling plaque and gingivitis: A systematic review and meta‐analysis.Int. J. Dent. Hyg.2022201536110.1111/idh.1251834013606
     [Google Scholar]
  53. van BodegravenE.A. van RamshorstT.M.E. BalduzziA. HilalM.A. MolenaarI.Q. SalviaR. van EijckC. BesselinkM.G. Routine abdominal drainage after distal pancreatectomy: Meta-analysis.Br. J. Surg.2022109648648810.1093/bjs/znac04235576374
     [Google Scholar]
  54. TsampasianV. ElghazalyH. ChattopadhyayR. AliO. CorballisN. ChousouP.A. ClarkA. GargP. VassiliouV.S. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis.Eur. J. Prev. Cardiol.2022296e227e22910.1093/eurjpc/zwab18934850881
     [Google Scholar]
  55. FungJ.Y.T. LimH. VongsirimasN. Klainin-YobasP. Effectiveness of eHealth mindfulness-based interventions on cancer-related symptoms among cancer patients and survivors: A systematic review and meta-analysis.Journal of Telemedicine and Telecare20221357633X22107849010.1177/1357633X22107849035212553
     [Google Scholar]
  56. WongG.L.H. ChanH.L.Y. ChoiP.C.L. ChanA.W.H. YuZ. LaiJ.W.Y. ChanH.Y. WongV.W.S. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B.Aliment. Pharmacol. Ther.201439219720810.1111/apt.1255924261924
     [Google Scholar]
  57. NaveauS. LamouriK. PourcherG. Njiké-NakseuM. FerrettiS. CourieR. TranchartH. GhinoiuM. BalianA. PrévotS. PerlemuterG. DagherI. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD.Obes. Surg.201424101693170110.1007/s11695‑014‑1235‑924841950
     [Google Scholar]
  58. ImajoK. KessokuT. HondaY. TomenoW. OgawaY. MawatariH. FujitaK. YonedaM. TaguriM. HyogoH. SumidaY. OnoM. EguchiY. InoueT. YamanakaT. WadaK. SaitoS. NakajimaA. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography.Gastroenterology20161503626637.e710.1053/j.gastro.2015.11.04826677985
     [Google Scholar]
  59. LeeH.W. ParkS.Y. KimS.U. JangJ.Y. ParkH. KimJ.K. LeeC.K. ChonY.E. HanK.H. Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease.PLoS One2016116e015735810.1371/journal.pone.015735827284700
     [Google Scholar]
  60. LoongT.C.W. WeiJ.L. LeungJ.C.F. WongG.L.H. ShuS.S.T. ChimA.M.L. ChanA.W.H. ChoiP.C.L. TseY.K. ChanH.L.Y. WongV.W.S. Application of the combined fibrometer vibration-controlled transient elastography algorithm in chinese patients with non-alcoholic fatty liver disease.J. Gastroenterol. Hepatol.20173271363136910.1111/jgh.1367127936280
     [Google Scholar]
  61. ForlanoR. MauriceJ. MullishB.H. AngkathunyakulN. GoldinE. ServiddioG. YeeM. GiannakeasN. TzallasA.T. TsipourasM.G. KhanS. Taylor-RobinsonS. GoldinR.D. ThurszM. ManousouP. The severity of steatosis does not influence liver stiffness measurements in patients with Non-Alcoholic Fatty Liver Disease.J. Hepatol.2017661S586S58710.1016/S0168‑8278(17)31598‑2
     [Google Scholar]
  62. GargH. AggarwalS. Shalimar YadavR. Datta GuptaS. AgarwalL. AgarwalS. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.Surg. Obes. Relat. Dis.2018141819110.1016/j.soard.2017.09.00529126863
     [Google Scholar]
  63. RungeJ.H. SmitsL.P. VerheijJ. DeplaA. KuikenS.D. BaakB.C. NederveenA.J. BeuersU. StokerJ. MR spectroscopy–derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis.Radiology2018286254755610.1148/radiol.201716293128915103
     [Google Scholar]
  64. EddowesP.J. SassoM. AllisonM. TsochatzisE. AnsteeQ.M. SheridanD. GuhaI.N. CobboldJ.F. DeeksJ.J. ParadisV. BedossaP. NewsomeP.N. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology201915661717173010.1053/j.gastro.2019.01.04230689971
     [Google Scholar]
  65. SiddiquiM.S. VuppalanchiR. Van NattaM.L. HallinanE. KowdleyK.V. AbdelmalekM. Neuschwander-TetriB.A. LoombaR. DasarathyS. BrandmanD. DooE. TonasciaJ.A. KleinerD.E. ChalasaniN. SanyalA.J. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease.Clin. Gastroenterol. Hepatol.2019171156163.e210.1016/j.cgh.2018.04.04329705261
     [Google Scholar]
  66. OoiG.J. MgaiethS. EslickG.D. BurtonP.R. KempW.W. RobertsS.K. BrownW.A. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.Obes. Rev.201819228129410.1111/obr.1262829119725
     [Google Scholar]
  67. JalalZ. IriartX. De LédinghenV. BarnetcheT. HiriartJ.B. VergniolJ. FoucherJ. ThamboJ.B. Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases.Heart2015101181499150410.1136/heartjnl‑2014‑30738526085526
     [Google Scholar]
  68. BehairyB.E.S. SiraM.M. ZalataK.R. SalamaE.S.E. Abd-AllahM.A. Transient elastography compared to liver biopsy and morphometry for predicting fibrosis in pediatric chronic liver disease: Does etiology matter?World J. Gastroenterol.201622164238424910.3748/wjg.v22.i16.423827122674
     [Google Scholar]
  69. Nguyen-KhacE. ThieleM. VoicanC. NahonP. MorenoC. BoursierJ. MuellerS. de LedinghenV. StärkelP. Gyune KimS. FernandezM. MadsenB. NaveauS. KragA. PerlemuterG. ZiolM. ChatelainD. DioufM. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: An individual patient data meta-analysis.Lancet Gastroenterol. Hepatol.20183961462510.1016/S2468‑1253(18)30124‑929983372
     [Google Scholar]
  70. DincsesE. YilmazY. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.Eur. J. Gastroenterol. Hepatol.201527101149115310.1097/MEG.000000000000040926049712
     [Google Scholar]
  71. AlkhouriN. DixonL.J. FeldsteinA.E. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal.Expert Rev. Gastroenterol. Hepatol.20093444545110.1586/egh.09.3219673631
     [Google Scholar]
  72. MahadevaS. MahfudzA.S. VijayanathanA. GohK.L. KulenthranA. CheahP.L. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease.J. Dig. Dis.2013141160461023859493
     [Google Scholar]
  73. VuppalanchiR. SanyalA.J. Myths and mysteries about staging hepatic fibrosis by fibroscan.Clin. Gastroenterol. Hepatol.201513478078210.1016/j.cgh.2014.10.03025451885
     [Google Scholar]
  74. FernandesF.F. FerrazM.L. AndradeL.E. DellavanceA. TerraC. PereiraG. PereiraJ.L. CamposF. FigueiredoF. PerezR.M. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients.J. Clin. Gastroenterol.201549323524110.1097/MCG.000000000000012824714186
     [Google Scholar]
  75. AttiaD. BantelH. LenzenH. MannsM.P. GebelM.J. PotthoffA. Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients.Aliment. Pharmacol. Ther.201644436637910.1111/apt.1371027363528
     [Google Scholar]
  76. RinaldiL. PafundiP.C. GalieroR. CaturanoA. MoroneM.V. SilvestriC. GiordanoM. SalvatoreT. SassoF.C. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review.Antioxidants202110227010.3390/antiox1002027033578702
     [Google Scholar]
  77. Maciejewska-MarkiewiczD. StachowskaE. HawryłkowiczV. StachowskaL. ProwansP. The role of resolvins, protectins and marensins in non-alcoholic fatty liver disease (NAFLD).Biomolecules202111793710.3390/biom1107093734202667
     [Google Scholar]
  78. MajumdarA. VerbeekJ. TsochatzisE.A. Non-alcoholic fatty liver disease: Current therapeutic options.Curr. Opin. Pharmacol.2021619810510.1016/j.coph.2021.09.00734688168
     [Google Scholar]
  79. PetroniM.L. BrodosiL. BugianesiE. MarchesiniG. Management of non-alcoholic fatty liver disease.BMJ2021372m474710.1136/bmj.m474733461969
     [Google Scholar]
  80. MascaróC.M. BouzasC. TurJ.A. Association between non-alcoholic fatty liver disease and mediterranean lifestyle: A systematic review.Nutrients20211414910.3390/nu1401004935010923
     [Google Scholar]
  81. MantovaniA. CsermelyA. PetraccaG. BeatriceG. CoreyK.E. SimonT.G. ByrneC.D. TargherG. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis.Lancet Gastroenterol. Hepatol.202161190391310.1016/S2468‑1253(21)00308‑334555346
     [Google Scholar]
  82. LiJ. ZouB. YeoY.H. FengY. XieX. LeeD.H. FujiiH. WuY. KamL.Y. JiF. LiX. ChienN. WeiM. OgawaE. ZhaoC. WuX. StaveC.D. HenryL. BarnettS. TakahashiH. FurusyoN. EguchiY. HsuY.C. LeeT.Y. RenW. QinC. JunD.W. ToyodaH. WongV.W.S. CheungR. ZhuQ. NguyenM.H. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis.Lancet Gastroenterol. Hepatol.20194538939810.1016/S2468‑1253(19)30039‑130902670
     [Google Scholar]
  83. GolabiP. PaikJ.M. AlQahtaniS. YounossiY. TuncerG. YounossiZ.M. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from global burden of disease 2009-2019.J. Hepatol.202175479580910.1016/j.jhep.2021.05.02234081959
     [Google Scholar]
  84. SwainM.G. RamjiA. PatelK. SebastianiG. ShaheenA.A. TamE. MarottaP. ElkhashabM. BajajH.S. EstesC. RazaviH. Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study.CMAJ Open202082E429E43610.9778/cmajo.2019021232518095
     [Google Scholar]
  85. AbenavoliL. BoccutoL. FedericoA. DallioM. LoguercioC. Di RenzoL. De LorenzoA. Diet and non-alcoholic fatty liver disease: The Mediterranean way.Int. J. Environ. Res. Public Health20191617301110.3390/ijerph1617301131438482
     [Google Scholar]
  86. YounossiZ.M. Non-alcoholic fatty liver disease – A global public health perspective.J. Hepatol.201970353154410.1016/j.jhep.2018.10.03330414863
     [Google Scholar]
  87. DaneshH. GhasabehS.R. RounasiR. ZarepurE. AbdolrazaghnejadA. Medical evaluation of test results related to covid 19 in iranian hospitals using quadas-2 to evaluate the quality of studies and meta-analysis using stata/mp v. 16 software.Journal of Medicinal and Chemical Sciences202222723810.26655/JMCHEMSCI.2022.2.10
     [Google Scholar]
  88. LiangZ. ZhangQ. WangC. ShiF. CaoH. YuY. ZhangM. LiuX. Hyaluronic acid/ hyaluronidase as biomarkers for bladder cancer: A diagnostic meta-analysis.Neoplasma201764690190810.4149/neo_2017_61228895415
     [Google Scholar]
  89. WittB.L. SchmidtR.L. Ultrasound-guided core needle biopsy of salivary gland lesions: A systematic review and meta-analysis.Laryngoscope2014124369570010.1002/lary.2433923929672
     [Google Scholar]
  90. WhitingP.F. RutjesA.W. WestwoodM.E. MallettS. DeeksJ.J. ReitsmaJ.B. QUADAS-2: Strumento per valutare la qualità degli studi di accuratezza diagnostica.Evidence201682e1000131
     [Google Scholar]
  91. FawcettT. An introduction to ROC analysis.Pattern Recognit. Lett.200627886187410.1016/j.patrec.2005.10.010
     [Google Scholar]
  92. BradleyA.P. The use of the area under the ROC curve in the evaluation of machine learning algorithms.Pattern Recognit.19973071145115910.1016/S0031‑3203(96)00142‑2
     [Google Scholar]
  93. MyersonJ. GreenL. WarusawitharanaM. Area under the curve as a measure of discounting.J. Exp. Anal. Behav.200176223524310.1901/jeab.2001.76‑23511599641
     [Google Scholar]
  94. WójcikowskiM. BallesterP.J. SiedleckiP. Performance of machine-learning scoring functions in structure-based virtual screening.Sci. Rep.2017714671010.1038/srep4671028440302
     [Google Scholar]
  95. JollansL. BoyleR. ArtigesE. BanaschewskiT. DesrivièresS. GrigisA. MartinotJ.L. PausT. SmolkaM.N. WalterH. SchumannG. GaravanH. WhelanR. Quantifying performance of machine learning methods for neuroimaging data.Neuroimage201919935136510.1016/j.neuroimage.2019.05.08231173905
     [Google Scholar]
  96. MetzC.E. Basic principles of ROC analysis.Semin. Nucl. Med.19788428329810.1016/S0001‑2998(78)80014‑2112681
     [Google Scholar]
/content/journals/cmim/10.2174/1573405619666230223092125
Loading
Alcoholic/Nonalcoholic Fatty Liver Disease Detection with Transient Elastography: A Detailed Review and Meta-analysis
20, e230223213941 (2024); https://doi.org/10.2174/1573405619666230223092125
/content/journals/cmim/10.2174/1573405619666230223092125
/content/journals/cmim/10.2174/1573405619666230223092125
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Assessment; Controlled attenuation parameter; Fatty liver disease; Liver; Liver stiffness measurement; Transient elastography

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test